Full Text View
Tabular View
Study Results
Related Studies
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure (ESCAPE-SHF)
This study has been completed.
Study NCT00923156   Information provided by Novartis

First Received on June 17, 2009.   Last Updated on July 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Heart Failure
Additional conditions recognized in this trial
Heart Failure, Systolic
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Interventions listed in this trial
aliskiren
ramipril
Placebo to aliskiren
Placebo to ramipril
Additional drug interventions recognized in this trial
Angiotensin II
Natriuretic Peptide, Brain
More general drug interventions related to this trial
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services